Skip Navigation
Bookmark and Share
.
Clinical Decision Making
Clinical Decision Making
Prescription drugs are prescribed during clinical encounters. Thorough and effective patient-provider communication about the benefits, risks, costs and alternatives to prescription medicines is a vital part of clinical care. The Center supports research and advocacy to identify and overcome barriers to patient-provider communication to improve safe medication use and to maximize adherence.
Comparative Effectiveness
Comparative Effectiveness
For stakeholders to make informed decisions about prescription drug use, they need timely evidence about the comparative effectiveness of therapies and their alternatives, including their risks and benefits. Incomplete evidence contributes to overuse of some therapies, underuse of others and risky prescribing. The Center supports innovative research into these topics.
Global Medicines
Global Medicines
Ensuring adequate access and affordability of prescription medicines poses major and unique challenges for countries around the world. These challenges are particularly salient in emerging economies that account for an increasing proportion of the world's population and pharmaceutical expenditures. Center investigators focus on how public policy can be optimized to maximize global drug availability and access.
Medication Safety
Medication Safety
Some adverse effects of medicines only come to light after medications have been on the market and widely used. Center investigators are working to develop new methods for identifying risk, to predict the likelihood of high-risk medicines or drug combinations and to protect the public from excessive exposure to these products.
Policy Analyses
Policy Analyses
Complex and dynamic policies govern prescription drug regulation. Policymakers face the challenge of maximizing innovation while protecting public health, and developing payment policies that promote evidence-based usage. Center investigators evaluate regulatory policies to provide policymakers with information to continually optimize pharmaceutical regulation.
Prescription Abuse
Prescription Abuse
Prescription drugs provide therapeutic value to millions of Americans. At the same time, rates of prescription drug abuse and overdose deaths are skyrocketing. The annual number of fatal drug overdoses in the United States now surpasses those of motor vehicle deaths. The Center supports innovative research and public advocacy to help stem this epidemic.

Craig Hendrix

Professor
Director, Drug Development Unit
Department Pharmacology and Molecular Sciences and Epidemiology

kayDr. Hendrix is a Professor in the Department of Medicine for Pharmacology and Molecular Sciences and Epidemiology as well as the interim Director of the division of clinical pharmacology and the Director of the Johns Hopkins University Drug Development Unit.

Dr. Hendrix has many research projects he is involved with that are all focused on the topic of HIV. One out of many NIH supported projects he is working on is a “Combination HIV Antiretroviral Rectal Microbicide Program.” In this program combination antiretroviral microbicides formulated in a gel optimized as a rectal application are being used and tested as a prevention of HIV transmission caused by anal intercourse. Another NIH supported project Dr. Hendrix is working on is entitled “Exploratory pharmacokinetics of dapivirine and Tenofovir vaginal microbicide gel v film.” This project’s purpose is to develop the first combination antiretroviral vaginal microbicide formulation, in both a gel and film formulation.

Dr. Hendrix received his S.B. in applied biology at the Massachusetts Institute of Technology and received his M.D. at Georgetown University School of Medicine.

To learn more about Dr. Hendrix, click here

johns hopkins

.
Subscribe:
  • Receive our Johns Hopkins
    Public Health Magazine,
    Public Health News
.